Product
Vusolimogene oderparepvec
1 clinical trial
1 indication
Indication
MelanomaClinical trial
Phase I Pilot Study of RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node MetastasisStatus: Recruiting, Estimated PCD: 2026-01-31
1 clinical trial
1 indication